Author(s):
M. Logeshwary, I. Somasundaram
Email(s):
somous0926@gmail.com
DOI:
10.5958/0974-360X.2020.00289.9 
Address:
M. Logeshwary1, I. Somasundaram2
1Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Instuite of Science, Technology and Advance Studies (VISTAS), Pallavaram, Chennai - 600117, Tamil Nadu, India.
2Department of Pharmaceutics , School of Pharmaceutical Sciences, Vels Instuite of Science, Technology and Advance Studies (VISTAS), Pallavaram, Chennai - 600117, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 3,
Year - 2020
ABSTRACT:
Diabetic foot ulcer (DFU) is a long term serious complication associated with diabetes and is defined as the ulceration in diabetic patients caused due to peripheral neuropathy and peripheral arterial disease of lower limbs. It is one of the major and leading causes of lower extremity amputations and increased morbidity. Increased podiatric pressure, abnormal glycemic parameters and many other causes leads to healing and non- healing ulcers in diabetic patients. Quality of life in DFU patients vary depending upon the stages of ulcers and duration of ulcers. DFU patients with healed ulcer will have higher quality of life than the patient with non- healed and chronic ulcers. Health related quality of life decreased progressively with the poor healing of wounds. In current scenario biomarkers are playing a major role in drug discovery, preclinical pharmacological studies, clinical trials and post marketing studies.The general biomarker discussed in this review are transforming growth factor, procalcitonin, calprotectin, cystatinC, Osteoprotegerin-1, edothelin- 1, CXCL-6, CXCL-12, Epithelial neutrophil activator, hypoxia inducible factor-1, Growth factors, Nitric oxide, Stem progenitor cell, Matrix metalloproteinase, Fibrinogen and Serpin B3. These above mentioned biomarkers are gaining importance in current scenario thus reducing morbidity and mortality rate.
Cite this article:
M. Logeshwary, I. Somasundaram. Quality of Life and Increasing Role of Biomarkers in Diagnosis, Prognosis and Prediction of Diabetic Foot Ulcer. Research J. Pharm. and Tech 2020; 13(3): 1597-1600. doi: 10.5958/0974-360X.2020.00289.9
Cite(Electronic):
M. Logeshwary, I. Somasundaram. Quality of Life and Increasing Role of Biomarkers in Diagnosis, Prognosis and Prediction of Diabetic Foot Ulcer. Research J. Pharm. and Tech 2020; 13(3): 1597-1600. doi: 10.5958/0974-360X.2020.00289.9 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-3-94
REFERENCE:
1. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ER, Whalley AM, Widdows P, Williamson S, Boulton AJ; North-West Diabetes Foot Care Study. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002 May;19(5): 377-84.
2. Centers for Disease Control and Prevention (CDC). Lower extremity disease among persons aged > or =40 years with and without diabetes--United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005 Nov 18;54(45):1158-60.
3. Lauterbach S1, Kostev K, Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J Wound Care. 2010 Aug;19(8):333-7.
4. Zhang P, Lu J1, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis †. Ann Med. 2017 Mar;49(2):106-116.
5. Moxey PW, Gogalniceanu P, Hinchliffe RJ, Loftus IM, Jones KJ, Thompson MM, Holt PJ. Lower extremity amputations--a review of global variability in incidence. Diabet Med. 2011 Oct;28(10):1144-53.
6. Pengzi Zhang, Jing Lu, Yali Jing, et al. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. Ann Med 2017; 49: 106–116.
7. Nabuurs-Franssen MH1, Huijberts MS, NieuwenhuijzenKruseman AC, Willems J, Schaper NC. Health-related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia. 2005 Sep;48(9):1906-10. Epub 2005 Jul 2.
8. RenátaZeleníková, RadkaBužgová, Eva Janíková, DarjaJarošováEvaluation Of Quality Of Life Of Patients With Diabetic Foot Syndrome In Selected Health Care Facilities Of Moravian Silesian Region Ošetřovatelství a porodníasistence 2014;5(1):2-8
9. Bakri, Farisand H Allan, Ali andKhader, Yousef andYounes, NidalandAjlouni, Kamel. (2011). Prevalence of Diabetic Foot Ulcer and its Associated Risk Factors among Diabetic Patients in. Jordan Medical Journal. 46. 118-125.
10. Shan-shanzhang, Zheng-Yi Tang, Ping Fang, Hong-JieQian, Lei Xu, GuangNingNutritional status deteriorates as the severity of diabetic foot ulcers increases and independently associates with prognosis ExpTher Med. 2013 Jan; 5(1): 215–222.
11. Alex R, Ratnaraj B, Winston B, Samson Devakiruba D N, Samuel C, John J, Mohan VR, Prasad JH, Jacob K S. Risk factors for foot ulcers in patients with diabetes mellitus - A short report from Vellore, South India. Indian J Community Med 2010;35:183-5
12. Biomarkers Definitions Working Group.Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. ClinPharmacolTher. 2001 Mar;69(3):89-95.
13. Juan Ybarraa, Josep M. Poub, June Hart Romeoc, Javier Merced, JeroniJuradoe Transforming growth factor beta 1 as a biomarker of diabetic peripheral neuropathy: cross-sectional study Journal of Diabetes and Its Complications 24 (2010) 306–312
14. Fengmei Zhang, YuguoRen, Peng Liu, YufengRen,Debao Wang, Expression of TGF-β1 and miRNA-145 in patients with diabetic foot ulcers ExpTher Med. 2016 May; 11(5): 2011–2014.
15. Eneroth M, Apelqvist J, Stenström A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int. 1997 Nov;18(11):716-22.
16. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8.
17. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206–17.
18. Kordek A, Podraza W, Czajka R. Reliability of semiquantitative determination of procalcitonin serum concentrations in neonates. DiagnMicrobiol Infect Dis 2006;56:31–4.
19. Hammer S, Meisner F, Dirschedl P, Hammer C. Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. TransplImmunol1998;6:235–41.
20. Massara M, De Caridi G, Serra R, Barillà D, Cutrupi A, Volpe A, Cutrupi F, Alberti A, Volpe P. The role of procalcitonin as a marker of diabetic foot ulcer infection. Int Wound J. 2017 Feb;14(1):31-34. doi: 10.1111/iwj.12536. Epub 2015 Oct 28.
21. Owaysee, Hamid, Pourhassan, Abolfazl, Pourjafar, Hadi, Sadeghian, Parisa . Ansari, Fereshteh..Procalcitonin as a Biomarker for Diabetic Foot Ulcer. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry. 2018,18.
22. Chien-Chang Chen, yJing-Long Huang, zChee-Jen Chang, Man-Shan Kong Fecal Calprotectin as a Correlative Marker in Clinical Severity of Infectious Diarrhea and Usefulness in Evaluating Bacterial or Viral Pathogens in Children, JPGN 2012;55: 541–547.
23. J. R. Ingram , S. Cawley, E. Coulman, C. Gregory, E. Thomas-Jones, T. Pickles, R. Cannings-John, N. A. Francis, K. Harding, K. Hood, V. Piguet Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) Diabet Med. 2018
24. Thomas Clark Powell, John P Donnelly1, Orlando M Gutiérrez, Russell L Griffin, Monika M Safford, Henry E Wang, Cystatin C and long term risk of communityacquired sepsis: a population-based cohort study BMC Nephrology201516:61
25. BK Myke-Mbata1, SC Meludu, CE Dioka, PHOAmodu, Albumin-Creatinine Ratio is More Diagnostic Sensitive than Cystatin-C in Assessment of Diabetic Peripheral Neuropathy J Korean Med Sci. 2012 Jul; 27(7): 784–787.
26. Yanyun Hu1,2, Fang Liu1,2, Jing Shen1,2, Hui Zeng1, Lianxi Li1,2, Jun Zhao3, Jungong Zhao4, Fengdi Lu1 and Weiping Jia1,2 Association between serum cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population Eur J Endocrinol. 2014 Nov;171(5):641-8.
27. Jie Zhao, Wuquan Deng, Yuping Zhang, YanlingZheng, Lina Zhou, Johnson Boey, David G. Armstrong, Gangyi Yang, Ziwen Liang, and Bing Chen Association between Serum Cystatin C and Diabetic Foot Ulceration in Patients with Type 2 Diabetes: A Cross-Sectional Study J Diabetes Res. 2016; 8029340
28. Ligen Ai, BD; Yanyun Hu, MD, PhD; Xiaoyan Zhang, MD; Hui Zeng, BN; Jun Zhao, MD, PhD; Jungong Zhao, MD, PhD; Yimin Chai, MD, PhD; Junxi Lu, BD; Junling Tang, BD; YuqianBao, MD; Fang Liu, MD, PhD; WeipingJia, MD, PhD High cystatin C levels predict undesirable outcome for diabetic foot ulcerations Wound Repair Regen. 2016 May;24(3):560-7.
29. Pradana Soewondo1, Slamet Suyono1, MpuKanoko Sastrosuwignyo2, Alida R. Harahap3, Bambang Sutrisna4, Lukman H. Makmun1 Prediction of Wound Healing in Diabetic Foot Ulcers: an Observational Study in Tertiary Hospital in Indonesia Acta Med Indones. 2017 Jan;49(1):41-51.
30. Escandon J, Cipolla M. Diabetes and endothelial dysfunction. Endocrine Rev. 2001;22:36-52.
31. Yamauchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H. Enhanced secretion of endothelin-1 by elevated glucose level from cultured bovine aortic endothelial cells. FEBS Lett. 1990;267(1):16-8.
32. Park J-Y, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose an effect of protein kinase c activation. Diabetes. 2000;49(7):1239-48.
33. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin is associated with silent coronary artery disease in high risk but asymptomatic type 2 diabetic patients. Diab Care. 2005;28:2176-80.
34. M Malyankar, U andScatena, Marta andSuchland, Katherine and J Yun, T and Clark, Edward and M Giachelli, C. Osteoprotegerin Is an alpha vbeta 3-induced, NF-kappa B-dependent Survival Factor for Endothelial Cells. The Journal of biological chemistry. 200,275. 209 59-62.
35. Falanga V. Wound healing and its impairment in the diabetic foot. Lance, 2005, 366 (9498), 1736–1743 .
36. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature, 2018, 453 (7193), 314–321.
37. XiufangWang, Juyi Li, Zhongjing Wang,Aiping Deng Wound exudate CXCL6: a potential biomarker for wound healing of diabetic foot ulcers Biomark Med. 2019 Feb;13(3):167-174.
38. Amber L Beitelshees1, Christina. L Aquilante, HoomanAllayee, Taimour Y Langaee, Gregory J Welder4, Richard S Schofiel, IssamZineh CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults Beitelshees et al. Human Genomics 2012, 6:9
39. Ju-yi Li, Zhong-jing Wang, Ai-ping Deng, and Yu-ming Li, “ENA-78 Is a Novel Predictor of Wound Healing in Patients with Diabetic Foot Ulcers,” Journal of Diabetes Research, vol. 2019, Article ID 2695436, 9 pages, 2019.
40. E. Nedeau, R. J. Bauer, K. Gallagher, H. Chen, Z. J. Liu, and O. C. Velazquez, “A CXCL5- and bFGF-dependent effect of PDGF-B-activated fibroblasts in promoting trafficking and differentiation of bone marrow-derived mesenchymal stem cells,” Experimental Cell Research,2008, vol. 314, no. 11-12, pp. 2176–2186.
41. De Donatis, F. Ranaldi, and P. Cirri, “Reciprocal control of cell proliferation and migration,” Cell Communication and Signaling: CCS,2010, vol. 8, no. 1, p. 20.
42. L. Himmlova, D. Kubies, H. Hulejova et al., “Effect of blood component coatings of enosseal implants on proliferation and synthetic activity of human osteoblasts and cytokine production of peripheral blood mononuclear cells,” Mediators of Inflammation,2006, vol. 2016, Article ID 8769347, 15 pages.
43. Madlener M, Parks WC, Werner S. Matrix metalloproteinase (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Experimental Cell Research. 1998;242(1):201-210
44. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinase and growth factors in diabetic foot wounds treated with a protease absorbent dressing. Journal of Diabetes and its Complications. Diabet Med. 2008 Apr 1; 25(4): 419–426.
45. Yu Liu, Md1 Danqing Min, PHD Thyra Bolton , Vanessa Nub´E, Stephen M. Twigg, Increased Matrix Metalloproteinase-9 Predicts Poor Wound Healing in Diabetic Foot Ulcers Diabetes Care 32:117–119, 2009